Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Feasibility And Safety Study Of rhBMP-2/CPM For Hip Fractures

ClinicalTrials.gov ID: NCT00384358

Public ClinicalTrials.gov record NCT00384358. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Single-Blind, Randomized, Stratified, Standard-Of-Care Controlled, Feasibility And Safety Study Of rhBMP-2/CPM As An Adjuvant Therapy For Fractures Of The Proximal Femur

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess the safety of administering rhBMP-2/CPM as an adjuvant to internal fixation in subjects with fractures of the proximal femur.

Study identification

NCT ID
NCT00384358
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
108 participants

Conditions and interventions

Conditions

Interventions

Drug · Other

Eligibility (public fields only)

Age range
55 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2006 (Type not available)
Primary completion
Jun 2010 (Actual)
Completion
Jun 2010 (Actual)
Last update posted
Feb 28, 2013

2006 – 2010

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
8
Facility City State ZIP Site status
Pfizer Investigational Site Aurora Colorado 80012 —
Pfizer Investigational Site New Haven Connecticut 06520 —
Pfizer Investigational Site Clearwater Florida 33756 —
Pfizer Investigational Site Pinellas Park Florida 33703 —
Pfizer Investigational Site Decatur Georgia 30033 —
Pfizer Investigational Site New Brunswick New Jersey 08903 —
Pfizer Investigational Site Brooklyn New York 11220 —
Pfizer Investigational Site Elmhurst New York 11373 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00384358, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 28, 2013 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00384358 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →